Showing results (211-220 of 228) with videos related to
Sort By:
Pageof 23
Science Translational Medicine|July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in BotswanaRoger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.Plos One|May 1, 2009
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners studyJairam R Lingappa, Erin Kahle, Nelly Mugo, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 10, 2016
Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 TrialJessica M Fogel, Sarah E Hudelson, San-San Ou, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 3, 2018
HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052Philip J Palumbo, Jessica M Fogel, Sarah E Hudelson, et al.The Lancet. Infectious Diseases|March 8, 2014
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialBeatriz Grinsztejn, Mina C Hosseinipour, Heather J Ribaudo, et al.The New England Journal of Medicine|July 20, 2011
Prevention of HIV-1 infection with early antiretroviral therapyMyron S Cohen, Ying Q Chen, Marybeth McCauley, et al.Plos Pathogens|July 20, 2016
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.Lancet (London, England)|February 16, 2010
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trialJairam R Lingappa, Jared M Baeten, Anna Wald, et al.Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.Plos Pathogens|September 26, 2017
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.Pageof 23